Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16 USD | +2.11% | -9.66% | -42.96% |
Jun. 04 | Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses | CI |
May. 09 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.96% | 861M | |
+49.41% | 56.95B | |
+40.83% | 40.26B | |
-6.72% | 39.32B | |
-5.96% | 28.37B | |
+12.99% | 26.45B | |
-19.82% | 19.41B | |
+32.35% | 12.54B | |
-0.08% | 12.15B | |
+25.18% | 12.21B |
- Stock Market
- Equities
- PHVS Stock
- News Pharvaris N.V.
- Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating